SavedAdd your journal

Journals / Turkish Journal of Hematology / 2021 / Cilt: 38 - Sayı: 3

Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients

Myelodisplazi İlişkili Değişiklikler Gösteren Akut Myeloid Löseminin Klinik Özellikleri ve Optimal Tedavisi: Çinli Hastalar Kohortunun Retrospektif Bir Analizi

Lei Wang
Li Li
Junqing Xu
Yinghui Liu
Xiaoxia Chu
Jingyao Wang
Licai An
Pages
188–194
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Compared with AML-NOS, patients with AML-MRC had significantly different clinical characteristics as well as worse overall survival (OS) (9.2 vs. 13.6 months; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to investigate the clinical characteristics of acute myeloid leukemia with myelodysplasia-related changes (AML- MRC) according to the 2016 World Health Organization classification and the preferred therapy for patients with AML-MRC aged 60-75 years.
📊
Key Findings & Data:Materials and Methods: We retrospectively analyzed differences in clinical data among 190 patients with AML-MRC and 667 patients with AML not otherwise specified (AML-NOS).
💡
Conclusion & Impact:Results: Compared with AML-NOS, patients with AML-MRC had significantly different clinical characteristics as well as worse overall survival (OS) (9.2 vs. 13.6 months; p
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to investigate the clinical characteristics of acute myeloid leukemia with myelodysplasia-related changes (AML- MRC) according to the 2016 World Health Organization classification and the preferred therapy for patients with AML-MRC aged 60-75 years. Materials and Methods: We retrospectively analyzed differences in clinical data among 190 patients with AML-MRC and 667 patients with AML not otherwise specified (AML-NOS). We also compared different therapeutic regimens among patients with AML-MRC aged 60-75 years. Results: Compared with AML-NOS, patients with AML-MRC had significantly different clinical characteristics as well as worse overall survival (OS) (9.2 vs. 13.6 months; p

Özet

Amaç: Bu çalışma, 2016 Dünya Sağlık Örgütü sınıflamasına göre myelodisplazi ilişkili değişiklikler gösteren akut myeloid löseminin (AML-MRC) klinik özelliklerini ve 60-75 yaş arası AML-MRC hastalarında tercih edilen tedaviyi araştırmayı amaçlamıştır. Gereç ve Yöntemler: AML-MRC’li 190 hasta ve başka şekilde tanımlanmamış AML’li (AML-NOS) 667 hasta arasındaki klinik farklılıkları geriye dönük olarak analiz ettik. Ayrıca 60-75 yaş arası AML-MRC’li hastalar arasında farklı terapötik rejimleri karşılaştırdık. Bulgular: AML-NOS ile karşılaştırıldığında, AML-MRC’li hastalar, daha kötü genel sağkalım (GS) (9,22’ye karşı 13,6 ay; p

🔖

Cite This Article

Wang, L., Li, L., Xu, J., Liu, Y., Chu, X., Wang, J., An, L. (2022). Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients. Turkish Journal of Hematology, Cilt: 38 - Sayı: 3, 188–194. https://ajindex.com/articles/606552

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. . Swerdlow S, Campo E, Lee Harris N. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008. 2. Daniel AA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau ML, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016
  2. Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddeman W. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003
  3. Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, Gotlib J, Zehnder JL, Arber DA. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 2009
  4. Yanada M, Suzuki M, Kawashima K, Kiyoi H, Kinoshita T, Emi N, Saito H, Naoe T. Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single center experience. Eur J Haematol 2005
  5. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017
  6. Jaffe ES, Harris NL, Stein H. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon, IARC Press, 2001. 8. Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D’Incan E, Charbonnier A, Blaise D, Mozziconacci MJ, Vey N. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients. Am J Hematol 2015
  7. E22-24. 9. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015
  8. Christman JK. 5-Azacytidi